篇名

止痛藥帶給藥廠的利益與反噬   免費試閱

並列篇名

The Benefits and Backlash of PainKillers to Pharmaceutical Companies

作者
中文摘要

2018年9月15日止痛處方藥奧施康定的生產商普渡製藥提交破產申請,以終止2000多個集體訴訟,並提供了一項天價和解協議,普度製藥等公司已因奧施康定案被罰款6.345億美元。奧施康定片劑應每12小時服用一次,自該藥於1995年問世一直面臨其他證據指控,包括:醫師投訴、銷售代表報告及獨立研究。製藥公司隱瞞此種藥物的危險性、積極廣告及銷售促進開立處方,並曾轉向教育醫師,使得許多人在1990年代後期開始以較短的間隔開立奧施康定處方。

英文摘要

On Sept. 15th, 2018, Purdue Pharma, maker of the prescription painkiller OxyContin, stated that it would file a bankruptcy petition to end those more than 2000 class actions. It has offered a settlement deal said to be worth as much as $12 billion maximum. It and the other pharmaceutical company Execs already in pay $634.5 million fine in which case. OxyContin tablets should be taken at 12-hourly intervals. Since the drug’s debut in 1995, the company has been confronted with additional evidence including complaints from doctors, reports from sales reps and independent research. The manufacturing companies concealed the dangers of such drug, they had no control over the problems of false commericals and mass sales which aroused over-prescription. They used to refocus and educate physicians to dispense those medicine. Then many doctors began prescribing OxyContin at shorter intervals in the late 1990s.

起訖頁

147-166

出版單位
DOI

10.3966/241553062020080046014  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP